Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis

Management of Graves’ orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients. Rituximab is a monoclonal antibody against CD20 antigen that is expressed in mature and immature B cells. Early experience with rituximab su...

Descripción completa

Detalles Bibliográficos
Autores principales: Şimşek, Tülay, Yıldırım, Nilgün, Efe, Belgin, Kebapçı, Nur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282540/
https://www.ncbi.nlm.nih.gov/pubmed/28182165
http://dx.doi.org/10.4274/tjo.26780
_version_ 1782503341831487488
author Şimşek, Tülay
Yıldırım, Nilgün
Efe, Belgin
Kebapçı, Nur
author_facet Şimşek, Tülay
Yıldırım, Nilgün
Efe, Belgin
Kebapçı, Nur
author_sort Şimşek, Tülay
collection PubMed
description Management of Graves’ orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients. Rituximab is a monoclonal antibody against CD20 antigen that is expressed in mature and immature B cells. Early experience with rituximab suggests that it is a promising alternative therapy for Graves’ orbitopathy. Here we report a case of a 49-year-old woman with Graves’ orbitopathy and psoriasis. The patient received 2 infusions of 1 g rituximab 2 weeks apart. Although there was improvement in inflammatory signs of the disease, proptosis did not change after the treatment.
format Online
Article
Text
id pubmed-5282540
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-52825402017-02-08 Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis Şimşek, Tülay Yıldırım, Nilgün Efe, Belgin Kebapçı, Nur Turk J Ophthalmol Case Report Management of Graves’ orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients. Rituximab is a monoclonal antibody against CD20 antigen that is expressed in mature and immature B cells. Early experience with rituximab suggests that it is a promising alternative therapy for Graves’ orbitopathy. Here we report a case of a 49-year-old woman with Graves’ orbitopathy and psoriasis. The patient received 2 infusions of 1 g rituximab 2 weeks apart. Although there was improvement in inflammatory signs of the disease, proptosis did not change after the treatment. Galenos Publishing 2017-01 2017-01-17 /pmc/articles/PMC5282540/ /pubmed/28182165 http://dx.doi.org/10.4274/tjo.26780 Text en © Copyright 2017 by Turkish Ophthalmological Association Turkish Journal of Ophthalmology, published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Şimşek, Tülay
Yıldırım, Nilgün
Efe, Belgin
Kebapçı, Nur
Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis
title Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis
title_full Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis
title_fullStr Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis
title_full_unstemmed Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis
title_short Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis
title_sort rituximab treatment in a patient with active graves’ orbitopathy and psoriasis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282540/
https://www.ncbi.nlm.nih.gov/pubmed/28182165
http://dx.doi.org/10.4274/tjo.26780
work_keys_str_mv AT simsektulay rituximabtreatmentinapatientwithactivegravesorbitopathyandpsoriasis
AT yıldırımnilgun rituximabtreatmentinapatientwithactivegravesorbitopathyandpsoriasis
AT efebelgin rituximabtreatmentinapatientwithactivegravesorbitopathyandpsoriasis
AT kebapcınur rituximabtreatmentinapatientwithactivegravesorbitopathyandpsoriasis

Ejemplares similares